These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7191278)

  • 41. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
    Sterner W; Chibanguza G; Metz G
    Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
    Baglin A; Lasserre N; Prinseau J; Lebas M
    Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
    [No Abstract]   [Full Text] [Related]  

  • 44. Simultaneous GLC determination of clofibrate and clofibric acid in human plasma.
    Wolf MS; Zimmerman JJ
    J Pharm Sci; 1980 Jan; 69(1):92-3. PubMed ID: 7354454
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bezafibrate does not influence the QT interval in man.
    Olsson AG; Ekelund LG; Lang PD; Vollmar J
    J Cardiovasc Pharmacol; 1983; 5(2):341-2. PubMed ID: 6188913
    [No Abstract]   [Full Text] [Related]  

  • 46. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Therapy of ischemic ulcers of the lower extremities using plafibride].
    Palou Monzo J; López-Delmás FJ
    Angiologia; 1984; 36(6):273-8. PubMed ID: 6517385
    [No Abstract]   [Full Text] [Related]  

  • 48. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R
    Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926
    [No Abstract]   [Full Text] [Related]  

  • 49. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
    Freyberger H; Schifferdecker E; Schatz H
    Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.
    Houin G; Shastri RA; Barre J; Pinchon B; Tillement JP
    Br J Clin Pharmacol; 1984 Mar; 17(3):341-5. PubMed ID: 6712867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment of coronary heart disease with diet and lipid-reducing agents].
    Sailer D; Kolb S
    Fortschr Med; 1982 Nov; 100(43):2005-10. PubMed ID: 7152437
    [No Abstract]   [Full Text] [Related]  

  • 52. [Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
    Vorberg G; Ziegler WJ
    Arzneimittelforschung; 1980; 30(11b):2068-72. PubMed ID: 7194062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
    Fincham JE; Quack G; Wülfroth P; Benadé AJ
    Arzneimittelforschung; 1996 May; 46(5):519-25. PubMed ID: 8737639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A quantitative gaschromatographic method for the determination of p-chlorophenoxyisobutyric acid (clofibrinic acid) in human plasma (author's transl)].
    Häselbarth V
    Arzneimittelforschung; 1976; 26(11):2076-80. PubMed ID: 1037251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
    Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Toxicological and pharmacological studies on a new drug: pirfibrate (EL-466) (author's transl)].
    de la Fuente R; Santos M
    Arch Farmacol Toxicol; 1980 Dec; 6(3):255-64. PubMed ID: 7305456
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of etofylline clofibrate on experimental thrombosis and platelet function.
    Sim AK; Davies ME; McCraw AP; Metz G
    Arzneimittelforschung; 1980; 30(11b):2042-5. PubMed ID: 7194057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological activities and side effects of plafibride.
    Gras J; Basi N; Zapatero J; Bermejo P; Gimenez F; Beascoa E; Llenas J; Bargalló MA; Giráldez A; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1808-16. PubMed ID: 6976173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
    Abshagen U; Kösters W; Kaufmann B; Lang PD
    Klin Wochenschr; 1980 Sep; 58(17):889-96. PubMed ID: 7442088
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.